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Novelty & Impact Statements: 
In the current study, we describe the complex role of PHD2 in tumor associated immune cells 
in a conditional PHD2-deficient mouse line. We demonstrate reduced tumor volume in these 
mutant mice as a consequence of opposing changes including the drastic down-regulation of 
numerous pro- as well as anti-tumoral genes and an imbalance between enhanced cell death 
and improved proliferation of tumor cells. Using different immune cell specific KO mice, we 
confined this complex phenotype to the crosstalk of PHD2-deficient myeloid cells and T-
lymphocytes.   
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Abstract 
The tumor microenvironment plays a pivotal role during cancer development and progression. 
The balance between suppressive and cytotoxic responses of the tumor immune 
microenvironment has been shown to have a direct effect on the final outcome in various 
human and experimental tumors. Recently, we demonstrated that the oxygen sensor HIF-
prolyl hydroxylase 2 (PHD2) plays a detrimental role in tumor cells, stimulating systemic 
growth and metastasis in mice. In the current study, we show that the conditional ablation of 
PHD2 in the hematopoietic system also leads to reduced tumor volume, intriguingly generated 
by an imbalance between enhanced cell death and improved proliferation of tumor cells. This 
effect seems to rely on the overall down regulation of pro- as well as anti-tumoral cytokines. 
Using different genetic approaches, we were able to confine this complex phenotype to the 
crosstalk of PHD2-deficient myeloid cells and T-lymphocytes. Taken together, our findings 
reveal a multifaceted role for PHD2 in several hematopoietic lineages during tumor 
development and might have important implications for the development of tumor therapies 
in the future. 
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Introduction 
Prolyl hydroxylase domain proteins (PHD 1-4) are enzymes which were originally described 
to hydroxylate subunits of the hypoxia transcription factors HIF1α and HIF2α, inducing their 
subsequent ubiquitination under normoxic conditions1. With decreased levels of oxygen these 
enzymes become less active, leading to the stabilization of the HIFα subunits. This in turn 
leads to the onset of HIF downstream adaptation processes, including angiogenesis, survival 
and metabolic alteration2. Furthermore, a number of non-HIF targets of PHDs have already 
been identified (reviewed in3) and even non-hydroxylase activities of PHDs were recently 
revealed4, 5. Our research group previously demonstrated that loss of PHD2 in different tumor 
cell lines leads to the transformation of TGFβ from a tumor promoter to a tumor suppressor, 
which resulted in a profound reduction in tumor growth6, 7. Contrary to our results, Chan and 
colleagues have revealed that loss of PHD2 in different human cell lines can lead to faster 
tumor growth, which they attributed to PHD2-mediated angiogenesis and bone marrow cell 
recruitment4. This highlights the important but also controversial role which PHD2 can 
assume in different tumor models and settings.  
In addition to neoplastic cells, the tumor microenvironment (TME), including stromal cells, 
endothelial and immune cells play an important role during tumor growth8. The latter cells 
typically originate from the bone marrow9. Different immune cells can be found in different 
amounts depending on the tumor origin and disease-stage. Although it has been well 
established that the immune system can induce an anti-tumor response10-12, we now know that 
this system can be manipulated by tumor cells to do the opposite13, 14. Indeed, tumor-
associated immune cells have been shown to promote tumor cell proliferation, angiogenesis, 
metastasis and immune escape15.  
In the present study, we investigated the direct effect of PHD2 gene-targeting in the 
hematopoietic system in relation to tumor development. We found reduced tumor growth in a 
recently described conditional PHD2 deficient mouse line which targets the entire 
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hematopoietic system16, 17. In order to unravel the background of this complex phenotype we 
focused on lineage specific PHD2-deficient mice (myeloid, T-cell and B-cell) and discovered 
that loss of PHD2 in both - myeloid and T-cells - is necessary and sufficient to reduce tumor 
growth. 
 
Materials and Methods 
 
Mice 
All mice were housed at the Experimental Centre at the University of Technology, Dresden 
(Medical Faculty, University Hospital Carl-Gustav Carus) and kept under specific pathogen-
free conditions. The characterization of the CD68:cre-PHD2f/f and CD68:cre-PHD2/HIF1αff/ff 
mouse line has recently been published16, 17. For bone marrow transplant experiments lethally 
irradiated B6.SJL (CD45.1) mice were transplanted with bone marrow from either CD68:cre-
PHD2f/f  or WT littermates (CD45.2). Uptake of donor bone marrow was verified by FACS 
using CD45.2/.1 antibodies. For tumor experiments, 1x106 Lewis Lung Carcinoma (LLC) 
cells or 5	  x105 B16BL6 melanoma cells were injected subcutaneously into both flanks of each 
mouse. Tumor volume (Volume = (Length x Width2)/2) was measured every second day for 
12 consecutive days using a caliper. Mice were then sacrificed and tumors isolated for flow 
cytometry analysis or frozen section preparation. All animal experiments were in accordance 
with the facility guidelines on animal welfare and were approved by the Landesdirektion 
Dresden, Germany. 
 
 
 
Histology 
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For necrosis analysis, tumors were placed in 4% formaldehyde at 4°C overnight, dehydrated, 
embedded in paraffin and cut. Sections were rehydrated and subjected to hematoxylin and 
eosin. For cryo-sections, samples were embedded in OCT, frozen, cut and stored at -20°C.  
For immunofluorescence analysis sections were first fixed for 10min in cold acetone and 
blocked with 5% goat serum (Vector labs, #VRC-S-1000) in TNT buffer (20mM Tris pH 7.6; 
0.9% NaCl, 0.05% Tween in PBS). Slides were then incubated with the following primary 
antibodies for either 1hr at 37°C or at 4°C overnight in TNT buffer: rat anti-PECAM  1:1000), 
rat anti-Ki67 (DAKO, 1:50), rabbit cleaved caspase3 (Cell Signaling, 1:150), HIF1α 
(Cayman, 1:100) and CD11b (eBioscience, 1:75). Primary antibodies were detected with a 
secondary antibody bound to Alexa-488 or Alexa-594 (Molecular Probes, 1:400) for 30 min 
at room temperature. Cell nuclei were stained with DAPI (Sigma, 1:5000). Slides were 
mounted with fluorescent mounting media (Dako). Fluorescent and light microscopy was 
done with an Axioplan-2 imaging microscope and plan Apochromat lenses (Carl Zeiss). The 
cameras and acquisition software were either Q Imaging Retiga 2000R and Image pro MC6.0 
(fluo) or Axiocam MRc5 and Axiovision (light). Representative images are presented from 
experiments with similar results. All quantifications were done using the NIH ImageJ 
software.  
 
Flow cytometry 
FACS analysis was performed on LSRII (Becton Dickinson), sorting was done on Aria II 
(Becton Dickinson). Data was analyzed on Flowjo (Treestar) software.  LLC tumors were 
isolated and single cell suspensions were prepared by manual mincing with a scalpel, 
followed by enzymatic digestion by Collagenase D 0.3U/ml (Roche), Dispase II 2.6U/ml 
(Roche ), DNase I 0.05 mg/ml (Roche) in DMEM for 40 min at 37°C. Enzymatic activity was 
quenched by adding DMEM containing 10% FCS, after which mixture was filtered through 
0.7µm nylon strainer (Sefar). Cells were then incubated for 40mins on ice with rat gamma 
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globulin (Jackson Immunoresearch), rat anti mouse CD16/CD32 (93), CD3 (APC, 145-2C11), 
CD4 (PE, GK1,5), CD8 (Pe-Cy5, ebioH35-17.2 (H35-17,2)), B220 (A700, RA3-6B2), CD45 
(Pe-Cy7, 30-F11), F4/80 (PE, BM8), Gr1 (A700, RB6-8C5), CD11b (FITC, M1/70 ) (all 
eBioscience), and DAPI (Molecular Probes) to discriminate between viable and dead cells. At 
least 6x10^5 cells were acquired. Cells were sorted according to the following antibodies: 
CD11b+Gr1-F4/80+ for TAM populations, and CD3+CD4+CD8- for CD4+ T cell population.   
 
Migration assay 
Cell culture chambers (insets of 5 µm pore size, Millipore) were used for the migration of the 
murine macrophage cell line RAW264.7 cells. RAW cells (1×105 cells/well) were placed in 
the upper chamber of the insert. Opti-MEM medium containing MCP-1 (10 ng/ml; R&D 
#479-JE) was placed in the lower chamber. All samples were incubated for 2h at 37˚C in a 
humidified atmosphere with 5% CO2. In the upper chamber, the non-invasive cells were 
removed by using a cotton swab and the invasive cells were fixed with methanol stained with 
hematoxylin. Migrated cells on the lower surface of the filter were counted and photographed 
using a light microscope at ×40 magnification. 
 
Expression analysis 
RNA from sorted cells was isolated using NucleoSpin RNA XS (Machery-Nagel). cDNA was 
synthesized using random primers (Roche) and superScript II (Invitrogen). Expression levels 
were determined by performing quantitative Real-time PCR using the Maxima SYBR Green 
QPCR Master Mix (Fermentas) on an iCycler iQ (Biorad). Sequences of primers used are 
given in Supplemental data. 
 
Statistical analysis 
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Data and graphs represent mean ± SEM of representative experiments. Statistical significance 
was calculated as two-tailed by students t-test (GraphPad Prism v5.04), with p<0.05 
considered statistically significant. 
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Results 
CD68:cre-PHD2f/f  mice display decreased tumor growth, at least partially dependent on 
HIF1α 
We have recently shown that conditional deficiency of PHD2 in erythropoietin (Epo)-
producing cells can lead to severe but non-lethal erythrocytosis16. In addition, these mice 
(CD68:cre-PHD2f/f) exhibited loss of PHD2 in the entire hematopoietic system and a subset 
of epithelial cells, but not in endothelium or fibroblasts. In order to study tumor development 
in this mouse line, we inoculated Lewis lung carcinoma (LLC) cells and monitored tumor 
growth for 12 days. Interestingly, already 6 days after inoculation, CD68:cre-PHD2f/f mice 
displayed smaller tumor volumes, which led to a significant difference by day 8 (Fig. 1A). 
Data from our group6, 7 and others4, 18 have suggested opposite roles for PHD2 depending on 
the tumor type. Therefore, we repeated the experiment with B16BL6 melanoma cells and 
once again found significantly reduced tumor volume in the same mouse line (Fig. 1B). 
Because of the linear growth pattern in the first 12 days, all further experiments were 
conducted using LLC cells. 
Since the CD68:cre-PHD2f/f mouse line was found to contain high Epo accompanied with 
high red blood cell (RBC) levels in circulation, we sought to find out whether this phenotype 
mediates the observed differences in tumor volume. Therefore, we repeated the tumor 
experiment in Epo transgenic mice (Epo Tg6), which display comparable hematocrit levels 
and slightly higher erythropoietin levels than our CD68:cre-PHD2f/f mice19. However, tumor 
growth in Tg6 mice and WT littermates showed no significant difference (Supplementary Fig. 
S1A), suggesting that the initial difference in tumor volume observed in CD68:cre-PHD2f/f 
mice is most probably not related to high Epo concentration in circulation.  
The main substrate of PHD2 is HIF1α and therefore we performed the tumor experiments 
again in CD68:cre-PHD2/HIF1αff/ff mice, CD68:cre-PHD2f/f and WT counterparts. These 
double deficient mice also display severe erythrocytosis but in contrast to the cKO mice these 
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mice die around 11 weeks of age due to neurodegeneration16. In this setup, tumor growth was 
followed for only 10 days, since several double deficient mice died shortly after this time 
point. Interestingly, in contrast to tumors grown in CD68:cre-PHD2f/f mice, tumors in 
CD68:cre-PHD2/HIF1αff/ff mice were not significantly different from WT controls and 
slightly larger than tumors in the PHD2 conditional deficient mice (Fig. 1C). This suggests 
that HIF1α might be at least partially responsible for the observed phenotype in CD68:cre-
PHD2f/f mice. In addition, we stained tumor sections from the latter mice and WT littermates 
for CD11b cells and HIF1α. Interestingly, and in contrast to WT tumors, we found that the 
majority of CD11b-positive myeloid cells in the tumors were also positive for HIF1α 
(Supplementary Fig. S1B).  
 
Loss of PHD2 in hematopoietic cells leads to decreased LLC tumor growth. 
In addition to the erythrocytosis phenotype and PHD2 targeting of the entire hematopoietic 
system, we also found loss of PHD2 in a few other cell types16. In order to undoubtedly 
validate that the reduced tumor growth is a consequence of targeting the hematopoietic 
system, we conducted bone marrow transplantation experiments. Whole bone marrow (BM) 
from either CD68:cre-PHD2f/f mice or WT littermates (CD45.2) was transplanted into lethally 
irradiated B6.SJL (CD45.1) recipients. Sixteen weeks after transplantation (>98% CD45.2 
PMNs in periphery of recipients (data not shown)) both groups were inoculated with LLC 
tumors. Interestingly, tumor growth in recipients that received cKO BM was significantly 
slower than in WT counterparts (Fig. 1D), similar to the growth retardation in non-
transplanted mice. These results strongly suggest that loss of PHD2 in hematopoietic cells 
alone is sufficient to reduce the tumor volume.  
 
Tumors in CD68:cre-PHD2f/f  mice display enhanced cell death but also increased 
proliferation 
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Recently, our group has found that PHD2 silencing in different mouse tumor cell lines is 
accompanied by the reduced proliferation potential of these tumor cells in vivo6. We were 
therefore interested to find out whether the slow growing tumors in the CD68:cre-PHD2f/f 
mice would display a similar phenotype. Surprisingly, we detected a nearly significant 
increase (p=0.07) in proliferating Ki67+ cells in the smaller tumors isolated from CD68:cre-
PHD2f/f mice compared with WT mice (Fig. 2A). Due to this discrepancy we investigated 
overall cell death in the different tumors. Quantitative analysis show twice as much necrosis 
in tumors grown in CD68:cre-PHD2f/f mice (Fig. 2B), but no significant difference in 
cleaved-caspase3; an indicator for apoptosis (Supplementary Fig. S1C). Furthermore, we6 and 
others4 have shown that silencing of PHD2 in tumor cells leads to induced vessel density, 
albeit in our earlier studies  (including LLC cells) it was accompanied with slower growth of 
the tumor6. We therefore investigated the endothelium in these tumors but found no difference 
in CD31-staining per area (Supplementary Fig. S1D) or in their functionality (data not shown) 
between both genotypes. Thus, loss of PHD2 in hematopoietic cells leads to reduced tumor 
growth due to increased necrosis, irrespective of the augmented proliferation rate found in the 
cKO tumors.  
 
Loss of PHD2 in immune cells does not affect their tumor-homing but leads to an overall 
reduction in cytokine production 
We were interested to figure out whether loss of PHD2 could influence the ability of immune 
cells to migrate and home to a solid tumor. In a Boyden chamber assay, we first tested the 
migration ability of the macrophage cell line RAW264.7 in which we silenced PHD2 with 
two different shPHD2 sequences (Supplementary Fig. S2A)7. For this purpose we used 
monocyte chemotactic protein-1 (MCP1 or CCL2) as a chemo-attractant since it has been 
shown previously that LLC cells produce this chemokine to attract monocytes/macrophages, 
while its inhibition can reduce tumor growth in vivo20. Interestingly, both PHD2-silenced 
11	  
	  
RAW cell lines showed significantly reduced migration compared to their controls 
(Supplementary Fig. S2B). In order to find a link between the reduced tumor growth and loss 
of PHD2 in vivo, we therefore quantified the percentage of immune cells present in the 
individual tumors of both genotypes at day 12 after inoculation. Despite the difference we 
found in vitro, we detected no significant changes in the percentage of white blood cells 
(CD45+) between tumors isolated from CD68:cre-PHD2f/f and WT mice (Fig. 3A), nor did we 
detect any significant difference in tumor associated macrophages (TAMS) 
(CD11b+F4/80+Gr1-), B cells (CD202), cytotoxic (CD3+CD8+) and helper (CD3+CD4+) T-
cells or myeloid derived suppressor cells (MDSCs) (CD11b+Gr1+) (Fig. 3B). These findings 
indicate that loss of PHD2 in immune cells has no influence on the ability of these cells to 
migrate and home to the solid tumor. Moreover, this result urged us to study the genetic 
profiles of some of the tumor associated inflammatory cell populations. First of all, we 
focused on the TAMs since they are the largest inflammatory population in the tumors. 
Moreover, a great amount of evidence has been collected exposing the importance of these 
cells in cancer immunology21, 22. Unlike the classical anti- (M1) or pro- (M2) tumor gene 
profile, we found that TAMs isolated from tumors taken out of CD68:cre-PHD2f/f mice 
showed overall lower expression of pro- as well as anti–inflammatory cytokines compared to 
controls. Indeed, we didn’t only find a significant reduction for TGFβ, iNOS, IL6 and TNFα, 
the vast majority of tested genes in PHD2 deficient TAMs showed reduced expression (Fig. 
3C). Remarkably, this image was also seen in isolated CD4+ T-cells (Fig. 3C), known to 
interact closely with TAMs in the context of solid tumors and metastasis (reviewed by23). 
These results imply that reduction of PHD2 in the hematopoietic system of cKO mice leads to 
a reduction of pro- as well as anti-tumoral genes in TAMs and CD4+ T-cells during tumor 
formation. 
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Conditional PHD2 down regulation in distinct immune cell lineages does not affect 
tumor growth 
Our results indicate that loss of PHD2 in the hematopoietic cells can lead to reduced tumor 
volume, and that TAMs as well as CD4+ T-cells show an overall down-regulation of pro- and 
anti-tumoral cytokines. We were therefore interested to find out which type of hematopoietic 
immune cells was responsible for the decreased tumor volume exhibited in the CD68:cre-
PHD2f/f mice. We concentrated on the main types of immune cells found in LLC tumors and 
developed PHD2 conditional deficient mouse lines for each one of them using previously 
described cre-recombinase mouse lines: LysM:cre for myeloid cells24, CD4:cre targeting all 
T-cell populations25 and CD19:cre for B cells26. As shown in Supplementary Fig. S3A-C, 
reduction of PHD2 was significantly different from WT mice in the appropriate immune cells 
isolated from tumor bearing transgenic mice. 
All mice were inoculated with LLC cells and tumor growth was measured every 2-3 days. In 
contrast to the results obtained in CD68:cre-PHD2f/f and BM transferred mice, several 
independent tumor experiments in all three PHD2 conditional KO mice showed no difference 
in tumor volume compared to their respective WT littermates (Fig. 4A-C). Thus, targeted 
down regulation of PHD2 solely in myeloid cells, T or B-cells is not responsible for the 
decrease in tumor volume observed in the cKO mice. 
 
Knock-out of PHD2 in myeloid and T-cells simultaneously reduces tumor growth. 
Although data from RNA expression analysis (Fig. 3B) did not indicate an explicit 
inflammatory response, it exhibited a change in the expression profile of two central immune 
populations; myeloid cells (TAMs) and T-cells (CD4+ T-cells). Building on these results and 
data from others groups27-30, implicating the cross talk between myeloid and T-cells in tumor 
development, we decided to target both populations simultaneously.  
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LLC cells were inoculated into LysM/CD4:cre-PHD2f/f and WT littermates, and tumor 
volume was monitored. Interestingly, several independent experiments showed a significant 
decrease in tumor growth in the double cre mice compared to their WT littermates (Fig. 5A). 
To find out whether the tumors from the CD4/LysM:cre-PHD2f/f mice exhibited similar 
proliferation increase and induction of cell death as found in tumors from the CD68:cre-
PHD2f/f mice we stained 12-day old tumors from both genotypes. Interestingly, the tumors 
from LysM/CD4:cre-PHD2f/f mice displayed a significant increase in proliferation (Ki67 
staining) as well as an augmentation of necrotic areas. In these genotypes we distinguished 
more apoptotic cells, although not significant, but again no difference in vessel density 
(Supplementary Fig. 4A and B respectively). 
Taken together, loss of PHD2 in myeloid cells and T-lymphocytes is necessary and sufficient 
to delay tumor growth in mice. 
 
Discussion 
Studies on the role of PHD2 during tumor development have been mainly limited to cancer 
cells, whereas not much is known on its effect in tumor associated inflammatory cells. In this 
report, we demonstrate reduced tumor growth in a mouse line deficient for PHD2 in several 
cell lineages. Via bone marrow transfer experiments as well as the combination of more 
confined lineage specific PHD2-deficient mice, we were able to bring back the observed 
phenotype to both the myeloid and T-cell compartment. Furthermore, we show that the 
reduced tumor volume is a consequence of opposing changes including the drastic 
transcriptional down-regulation of numerous pro- as well as anti-tumoral genes in the 
different immune cells and the induction of cell death together with increased tumor cell 
proliferation. 
Recent work from our research group in an LM8 osteosarcoma and LLC cell line has shown a 
direct influence of PHD2 on tumor growth in vivo6. In that report, PHD2 was silenced in the 
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tumor cells themselves and resulted in reduced growth. However, this growth retardation was 
accompanied by slower proliferation of the cells induced by TGFβ and an unexpected 
increase in vessel density. The current study reveals the importance of PHD2 in the 
hematopoietic system during the development of primary tumors. For this, we used our 
recently described CD68:cre-PHD2f/f mouse line that showed loss of PHD2 in the entire 
hematopoietic system, some subsets of epithelial cells as well as EPO expressing cells in 
kidney and brain, although not in fibroblasts and endothelial cells16, 17.  
The significantly reduced tumor volume in these conditional PHD2-deficient mice is not only 
shown in two independent tumor types, we also demonstrate that the growth difference in 
these erythrocytotic mice was independent of its high EPO levels, in contradiction to previous 
reports in other tumor settings31-33. Furthermore, the fact that LLC tumors are also smaller in 
mice transplanted with PHD2-deficient BM strongly suggests that the observed phenotype is 
confined to bone marrow derived cells.  
Interestingly, tumor experiments in CD68:cre-PHD2/HIF1αff/ff mice revealed no significant 
difference in tumor growth compared to WT littermates or CD68:cre-PHD2f/f mice. This 
implies that the observed phenotype may in part be driven by HIF1α but probably also by 
other factors. This could be either via hydroxylase-dependent and/or -independent activities as 
has been shown for the PHDs in different T-cell contexts before3, 4, 34-37. The differential 
effects that the loss of PHD2 has induced may therefore be a direct link to the unexpected 
gene profiles we observed in TAMs and CD4+ T-cells isolated from day 12 tumors. Indeed, 
several independent experiments demonstrated an overall down regulation of genes with an 
anti- (e.g. TNFα, IL1β, iNOS) as well as pro-tumoral (e.g. TGFβ, IL13) signature. These 
seemingly conflicting results are also reflected in the histology experiments we performed on 
these tumors. On the one hand, we observed significantly more cell death, but the same 
tumors also revealed a clear tendency towards more proliferating tumor cells. Taken together, 
our analysis suggests that in this particular setting, loss of PHD2 seems to generally reduce 
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the response in TAMs, helper T cells and potentially also other subtypes of tumor associated 
inflammatory cells (e.g. other T cells and/or MDSCs), which leads to opposing activities and 
ultimately smaller tumors. 
In another line of this study we wanted to unravel which BMDCs were responsible for the 
observed effects in our broad spectrum PHD2-deficient mouse line. Interestingly, we found 
that the combined knock-out of PHD2 in myeloid cells and T-lymphocytes was necessary and 
sufficient to obtain reduced tumor volumes as seen in CD68:cre-PHD2f/f mice. Furthermore, 
the tumors grown in LysM/CD4:cre-PHD2f/f mice also showed induced cell death combined 
with a very outspoken induction of Ki67. This apparent crosstalk between these two different 
classes of immune cells during tumor development is not new. Earlier results conducted by 
Denardo and colleagues27 as well as others38, 39 have emphasized the importance of the 
interaction between TAMs and CD4+ T lymphocytes in the context of solid tumors and 
metastasis (reviewed by 23). Indeed, adaptive immune responses by T lymphocytes can 
specifically regulate multiple pro-tumor properties of myeloid cells that in turn control many 
of the “hallmarks” of cancer development40. IL4 and IL13 are Th2 cytokines mainly produced 
by T-cells that have the ability to entice macrophages to turn into pro-tumoral M2 
macrophages by inducing the expression of genes like TGFβ, IL10 and Arg-127. In our study, 
we found that IL13 and TGFβ were consistently and significantly reduced whereas IL10 and 
IL4 showed at least a clear tendency to be downregulated. IL6, significantly reduced in the 
TAMs, is a pro-inflammatory cytokine but has also the potential, in addition to IL10 and 
TGFβ, to promote the differentiation and polarization of recruited monocytes into M2 
macrophages41. On the other hand, the Th1 cytokine IFNγ is able to induce antitumoral 
responses42, 43 and recently it was suggested that this could be mediated through the reversion 
of TAM-induced immunosuppression44. Our results did not only show a reduction of this 
cytokine in the CD4+ tumor associated cells, the TAMs also expressed significantly less 
iNOS, a vasodilator whose expression is known to be directly regulated by IFNγ45. In the 
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other direction, it was previously shown that TAMs can significantly affect the adaptive 
immune responses by inducing anergy of naïve T-cells or recruiting and stimulating 
regulatory T-cells and Th2 lymphocytes46. Thus, our data strongly imply that the availability 
and recognition of these soluble molecules, directly or indirectly via loss of PHD2 in immune 
cells, result in important paracrine interactions, which influence growth and viability of the 
tumor cells. 
Taken together, while our results do not implicate a single molecular pathway responsible for 
the decrease in tumor volume exhibited in CD68:cre-PHD2f/f and LysM/CD4:cre-PHD2f/f 
mice, they do portray an overall change in different parameters, which lead to the eventual 
decline in tumor volume. Our findings may also have interesting medical implications as 
specific PHD2 inhibitors may transform tumors to a less malignant and metastasizing 
phenotype; not only by the re-induction of the anti-proliferative TGFβ pathway in tumor 
cells7 but also, as shown in this study, by disturbing the pro-tumoral activity of the immune 
system.  
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Legends 
Figure 1.  Mice deficient for PHD2 in bone marrow-derived cells lead to decreased tumor 
volume. (A) LLC or (B) B16B6 cells were inoculated in CD68:cre-PHD2f/f mice and their WT 
littermates and tumor volume was measure every 2 days (n = 27-28 and n = 13-15 
respectively). (C) LLC cells were inoculated into mice deficient for PHD2 (CD68:cre-
PHD2f/f), deficient for both PHD2 and HIF1α (CD68:cre-PHD2/HIF1αff/ff)  and WT 
littermates (n = 7-21) and measured until day 10.  (D) LLC cells were inoculated into WT 
mice which received either bone marrow from CD68:cre-PHD2f/f mice (cKO BM -> WT) or 
bone marrow from PHD2f/f mice (WT BM-> WT) (n = 15-16). *P < 0.05; **P < 0.01 and 
***P < 0.001. 
Figure 2. Tumors in CD68:cre-PHD2f/f mice exhibit higher proliferation as well as increased 
necrosis. (A) Ki67 staining on tumor sections from WT and CD68:cre-PHD2f/f mice 
representing proliferative potential of the cells (n = 5). (B) H&E staining on tumor sections 
from WT and CD68:cre-PHD2f/f mice representing cell death (n = 5). *P < 0.05; Scale bars 
denote 100µm. 
Figure 3. Loss of PHD2 in bone-marrow derived cells does not affect homing ability. Single 
cell suspensions of day 12 LLC tumors were stained and analyzed via flow cytometry. (A) 
Flow cytometric analysis of total CD45+ cells in LLC tumor from CD68:cre-PHD2f/f and WT 
mice. Data depicted as mean percentage of total viable cells ± SEM (n = 4). (B) Flow 
cytometric analysis of individual groups of immune cells: B cells (B220+), CD4 T-cells 
(CD3+CD4+), CD8 T-cells (CD3+CD8+), TAMs (CD11b+Gr1-F4/80+) and MDSCs 
(CD11b+Gr1+). Data depicted as mean percentage of total CD45+ cells ± SEM (n = 4). (C) 
Cytokine expression by qPCR of TAMs and CD4+ T-cells sorted via FACS from 12 day LLC 
tumors. Expression depicted as fold change from WT expression (n = 5-10). *P < 0.05. 
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Figure 4. PHD2 deficient single-populations of leukocytes do not affect tumor volume in 
mice. LLC cells were inoculated in (A) myeloid (LysM:cre- PHD2f/f), (B) T-cell (CD4:cre- 
PHD2f/f) and (C) B cell (CD19:cre- PHD2f/f) PHD2 deficient mice. Tumor volume was 
measured every 2-3 days (n = 7-12). 
 
Figure 5.  Loss of PHD2 in myeloid and T-cells leads to decreased tumor volume. (A) LLC 
cells were inoculated in double cre mice deficient in PHD2 in both myeloid and T-cell 
compartments (CD4/LysM:cre- PHD2f/f) and WT control mice. Tumor volume was measured 
every 2 days (n = 7-16) * P < 0.05 and ** P < 0.01. (B) Ki67 staining (top) and H&E staining 
(bottom) of LLC tumor frozen sections from WT and CD4/LysM:cre-PHD2f/f mice (n=5 and 
7 respectively). Error bars represent ± SEM. Scale bars denote 100µm.  
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Supplementary figure 1: 
(A) Tg 6 mice and WT littermates were inoculated with LLC cells. 
Tumor volume was measured every 2 days for 12 days (n = 5-9).  
(B) IHC on tumor sections for HIF1α (Red)  and CD11b (Green). 
(C) Cleaved caspase-3 staining on frozen tumor sections from 
CD68:cre-PHD2f/f mice and WT littermates representing apoptosis 
of cells (n = 5-7). (D) CD31 staining of vessels on frozen tumor 
sections from WT and CD68:cre-PHD2f/f mice (n = 5). Error bars 
represent ± SEM and Scale bar denotes  25µm.  
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Supplementary figure 2: 
(A) RAW cells stably transfected with one of the shRNA constructs against PHD2 (P2.1 and P2.2) or sh scrambled (Scr) and control cells 
were tested for PHD2, HIF1α and βtubulin protein expression via western blot. (B) Migration assay for RAW shP2.1, shP2.2, shScr and 
RAW-C cells in a Boyden chamber (n = 5-8). Percentage of cells which migrated relative to the control cells (=100%). Error bars 
represent ± SEM. ***P < 0.001 
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Supplementary figure 3 
(A) Tumor associated macrophages (TAM) (CD11b+, F4/80+, GR1-) and (B) Tumor associated (TA)-CD4+ (CD3+CD4+) cells were isolated 
from 12 day old LLC tumors inoculated into CD4:cre-PHD2f/f or LysM:cre-PHD2f/f mice and WT littermates. (C) B-cells (CD19+) were 
isolated from the lymph nodes from naive CD19:cre-PHD2f/f mice. qPCR analysis of the isolated mRNA content relative to WT.  Error 
bars represent ± SEM. ***P < 0.001 
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Supplementary figure 4 
(A) Quantification of cleaved caspase-3 on frozen tumor sections isolated from CD4/LysM:cre-PHD2f/f mice and WT littermates 
representing apoptosis of tumor cells (n = 4-5). (B) % of CD31 staining (vessels ) on frozen tumor sections isolated from CD4/
LysM:cre-PHD2f/f mice and WT littermates (n = 4-5). Error bars represent ± SEM. 
 
